AC176-001 is a Phase I, first-in-human, open-label, multi-center dose-escalation study of AC176 given as a single agent. The AC176 is an investigational medicinal product that is a potent orally bioavailable Androgen Receptor (AR) degrader studied for the treatment of Metastatic Castration Resistant Prostate Cancer.
This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies.~The main goals of this study are to:~Identify the recommended dose of AC176 that can be given safely to participants~Evaluate the side effects of AC176~Evaluate pharmacokinetics of AC176~Evaluate the effectiveness of AC176